BioVersys AG | WebDisclosure

Basculer en Français

10913	Companies
238048	Keywords
166918	Articles
127882	Press releases

Home
Companies
BioVersys AG

PRESS RELEASE

published on 02/06/2025 at 07:00, 1 year 6 months ago

BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025
BioVersys successfully completes its IPO at CHF 36 per share, listing on SIX Swiss Exchange on February 07, 2025. The biopharmaceutical company focuses on antibacterial products against multidrug-resistant bacteria

IPO SIX Swiss Exchange Antibacterial Products BioVersys CHF 36
BRIEF

published on 01/29/2025 at 07:05, 1 year 7 months ago

BioVersys AG Launches IPO on SIX Swiss Exchange

SIX Swiss Exchange Share Offering BioVersys IPO Clinical Stage Biopharma Antibacterial Products
BRIEF

published on 01/29/2025 at 07:05, 1 year 7 months ago

BioVersys AG lance son introduction en bourse à la SIX Swiss Exchange

Offre D'actions Bourse Suisse SIX Introduction En Bourse De BioVersys Biopharma En Phase Clinique Produits Antibactériens
PRESS RELEASE

published on 01/29/2025 at 07:00, 1 year 7 months ago

BIOVERSYS LAUNCHES IPO ON THE SIX SWISS EXCHANGE AND SETS IPO PRICE AT CHF 36.00 PER SHARE
BioVersys launches IPO on the SIX Swiss Exchange with an IPO price set at CHF 36.00 per share. Offering expected to raise approximately CHF 80 million in gross proceeds including over-allotment option

IPO SIX Swiss Exchange Offering BioVersys CHF 36.00
BRIEF

published on 01/21/2025 at 07:09, 1 year 7 months ago

BioVersys AG Plans to Launch IPO on SIX Swiss Exchange

Antimicrobial Resistance SIX Swiss Exchange BioVersys IPO BV100 Clinical Trials Alpibectir Development
BRIEF

published on 01/21/2025 at 07:09, 1 year 7 months ago

BioVersys AG prévoit de lancer son introduction en bourse à la SIX Swiss Exchange

Bourse Suisse SIX Résistance Aux Antimicrobiens Introduction En Bourse De BioVersys Essais Cliniques BV100 Développement D'Alpibectir
PRESS RELEASE

published on 01/21/2025 at 07:04, 1 year 7 months ago

BIOVERSYS ANNOUNCES INTENTION TO FLOAT ON THE SIX SWISS EXCHANGE
BioVersys AG announces intention to float on SIX Swiss Exchange, targeting primary-only proceeds of approx. CHF 80 million to advance lead asset BV100 through Phase 3 and finance operating expenses. IPO supported by AMR Action Fund and GSK

IPO SIX Swiss Exchange BioVersys AG BV100 AMR Action Fund

Accesswire

Published on 09/01/2026 at 23:05, 11 hours 6 minutes ago

Aton Announces US$30M Credit Facility with OU Moonrider
Published on 09/01/2026 at 22:30, 11 hours 41 minutes ago

Algo Grande Copper Closes Oversubscribed Private Placement for $4.786 Million
Published on 09/01/2026 at 22:15, 11 hours 56 minutes ago

NuRAN Wireless Announces Plans to Voluntarily Delist from the Canadian Securities Exchange
Published on 09/01/2026 at 20:40, 13 hours 31 minutes ago

Tocvan Provides Corporate Update
Published on 09/01/2026 at 16:10, 18 hours 1 minute ago

Sparton Signs Definitive Morrison Silver Mine Option and Joint Venture Agreement with Glen Eagle; Appoints Vice President, Corporate Development

View all ACCESSWIRE

EQS Group

Published on 09/02/2026 at 10:05, 6 minutes ago

Thunes Champions Ethical Global Payments with its 2026 United Nations Global Compact Commitment
Published on 09/02/2026 at 10:05, 6 minutes ago

RingConn Showcases Gen 3 Smart Ring at IFA 2026
Published on 09/02/2026 at 10:05, 6 minutes ago

PANASONIC PIONEERS GLOBAL SHUTTER TECHNOLOGY WITH AW-UE200 & AW-UER200 PTZ SERIES
Published on 09/02/2026 at 10:05, 6 minutes ago

CIGRE 2026: Building power grids for a new age of electrification
Published on 09/02/2026 at 10:05, 6 minutes ago

BTL Establishes New Laser Division and Introduces EXOLASE ONE® - The World's First Fused Erbium Laser

Les Echos

Published on 09/02/2026 at 07:43, 2 hours 27 minutes ago

Accor launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2032 for a nominal amount of €380 million and a concurrent partial repurchase offer with respect to its outstanding OCEANEs due 2027 by
Published on 09/02/2026 at 07:43, 2 hours 27 minutes ago

Accor lance une émission d’obligations à option de conversion en actions nouvelles et/ou d’échange en actions existantes (OCEANEs) à échéance 2032 pour un montant nominal de 380 millions d’euros et une offre concomitante de rachat partiel de s
Published on 09/01/2026 at 19:00, 15 hours 11 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 09/01/2026 at 19:00, 15 hours 11 minutes ago

Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 09/01/2026 at 18:18, 15 hours 53 minutes ago

TF1 - Déclaration mensuelle des actions et droits de vote - Août 2026

View all LES ECHOS COMFI WIRE